Baker McKenzie Advises Servier on the Acquisition of Day One Biopharmaceuticals for Approximately USD 2.5 Billion

Advising firms

The announcement does not name individual lawyers.

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value

USD 2.50bn (approximately USD 2.5 billion)

What the figure measures

Total transaction value

Client

ServierBuy-side

Counterparties

Day One Biopharmaceuticals, Inc. (Target)